Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody

• Published in: Science (American Association for the Advancement of Science) Vol. 266; no. 5187; pp. 1024 - 1027
• Main Authors: Burton, Dennis R., Pyati, Jayashree, Koduri, Raju, Sharp, Stephen J., Thornton, George B., Paul W. H. I. Parren, Lynette S. W. Sawyer, Hendry, R. Michael, Dunlop, Nancy, Nara, Peter L., Lamacchia, Michael, Garratty, Eileen, Stiehm, E. Richard, Bryson, Yvonne J., Cao, Yunzhen, Moore, John P., Ho, David D., Barbas, Carlos F.
• Format: Journal Article
• Language: English
• Published: Washington, DC American Society for the Advancement of Science 11.11.1994; American Association for the Advancement of Science
• Subjects: Acquired Immunodeficiency Syndrome - virology; AIDS; AIDS vaccines; AIDS Vaccines - immunology; AIDS/HIV; Amino Acid Sequence; Antibodies; Antibodies, immunoglobulins; Antibodies, Monoclonal - immunology; Antibody Specificity; Biological and medical sciences; Enzyme linked immunosorbent assay; Fundamental and applied biological sciences. Psychology; Fundamental immunology; HIV 1; HIV Antibodies - immunology; HIV Core Protein p24 - analysis; HIV Envelope Protein gp120 - immunology; HIV-1 - immunology; HIV-1 - isolation & purification; human immunodeficiency virus 1; Humans; Immunization, Passive; Immunoglobulin Fab Fragments - immunology; Immunoglobulin G - immunology; Infant; Infant, Newborn; Infants; Libraries; Male; Molecular immunology; Molecular Sequence Data; Monoclonal antibodies; Neutralization Tests; Reactivity; Recombinant Proteins - immunology; Vaccination; Viruses; HIV-1 virus; Retroviridae; Glycoproteins; Vaccine; Monoclonal antibody; In vitro; Virus; Specificity; Lentivirinae; Property structure relationship; Human immunodeficiency virus; Recombinant protein; Neutralization
• ISSN: 0036-8075; 1095-9203
• DOI: 10.1126/science.7973652

The ability of antibodies to neutralize diverse primary isolates of human immunodeficiency virus-type 1 in vitro has been questioned, with implications for the likely efficacy of vaccines. A recombinant human antibody to envelope glycoprotein gp120 was generated and used to show that primary isolates are not refractory to antibody neutralization. The recombinant antibody neutralized more than 75 percent of the primary isolates tested at concentrations that could be achieved by passive immunization, for example, to interrupt maternal-fetal transmission of virus. The broad specificity and efficacy of the antibody implies the conservation of a structural feature on gp120, which could be important in vaccine design.